Skip to main content
Premium Trial:

Request an Annual Quote

Sanford-Burnham Receives $100M Donation, Changes Name

NEW YORK (GenomeWeb) – Sanford-Burnham Medical Research Institute announced today that it has received a $100 million donation from real estate developer and philanthropist Conrad Prebys.

In recognition of the donation, the institute also said that it is changing its name to Sanford Burnham Prebys Medical Discovery Institute.

The institute said that the money would help support a 10-year strategic plan, unveiled in early 2014, that is designed to accelerate innovation by "aligning basic biomedical research, translational research, and drug discovery and development."

The donation "enables us to conduct translational research to advance laboratory discoveries and clinic-ready drug candidates further along the development pipeline, progressing toward therapies, preventions, and cures for patients who desperately need them," Sanford-Burnham CEO Perry Nisen said in a statement. "We are profoundly grateful to Conrad Prebys for this extraordinary gift."

Prebys had previously donated $11 million to the institute, including $10 million to fund the Conrad Prebys Center for Chemical Genomics.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.